Bli medlem
Bli medlem

Du är här


aap: Successful start in 2015 with 45% LOQTEQ® sales increase and 23% growth in biomaterials business

aap Implantate AG / aap: Successful start in 2015 with 45% LOQTEQ® sales
increase and 23% growth inbiomaterials business . Processed and transmitted
by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
Implantate AG (XETRA: AAQ.DE) made a successful start to financial year 2015
with significant sales growth. According to preliminary figures, sales
increased in the first three months of this year compared to the
corresponding period in the last year by 16% to EUR 7.1 million (Q1/2014: EUR
6.1 million). Thereby the company exceeded its guidance provided in February
of EUR 6.5 million to EUR 7.0 million.

| Sales Q1/2015 Q1/2014 Change on year |
|in EUR million |
| Trauma 2.5 2.2 15% |
| thereof LOQTEQ® 1.7 1.1 45% |
| Biomaterials 4.4 3.6 23% |
| Projects 0.1 0.1 109% |
| Other 0.1 0.2 -81% |
| Total sales 7.1 6.1 16% |
The growth drivers of this positive sales performance in the first three
months of the current financial year were the LOQTEQ® product family and the
biomaterials business.aap
Implantate AG significantly increased sales with the LOQTEQ® portfolio in the
first quarter of 2015 year-on-year by 45% to EUR 1.7 million (Q1/2014: EUR
1.1 million). Performance in the reporting period testifies to the anatomic
plate system continuing to establish itself in the market.

Sustained by the significant growth in LOQTEQ® product sales,aap
Implantate AG's overall sales in the trauma business rose year-on-year by 15%
to EUR 2.5 million (Q1/2014: EUR 2.2 million). On a full year basis the
company's target is to achieve sales growth of more than 20% in the trauma
business. In order to achieve this target,aap
Implantate AG intends to expand the LOQTEQ® product family further in the
current financial year and thereby achieving an indication coverage of more
than 90%. Furthermore the company plans to push the internationalisation with
a focus on the US American market.

In the biomaterials business the company also achieved a significant sales
increase in the first quarter of 2015. Sales grew in the reporting period
compared to the first three months of financial year 2014 by 23% to EUR 4.4
million (Q1/2014: EUR 3.6 million). The growth driver in the first quarter of
the current year was in particular the bone cement business with global
leading companies.

Overall, it can be furthermore stated thataap
Implantate AG generates dynamic sales growth and pushes geographic expansion
with its innovative and IP protected LOQTEQ® products, while the biomaterials
business is characterized by continuous and profitable growth with strong
cash flows.

The preliminary results contained in this press release are based on
management's initial analysis of operations for the period ended on 31 March
2015, and are therefore subject to change.aap
Implantate AG plans to announce its final results for the first quarter of
2015 on 15 May 2015.

Implantate AG

is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that
are used in orthopedic procedures. The Company's products, which include a
full line of plating systems, cannulated screws and bone cement products, are
primarily used in the orthopedic specialty areas of trauma and spine repair.
The Company's products are sold through its direct sales force, distribution
partners and license agreements with OEM partners.aap
's stock is listed in the Prime Standard segment of the Frankfurt Stock
Exchange. For more information, please visit, or download the
Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. Many
factors could cause the actual results, performance or achievements of aap to
be materially different from those that may be expressed or implied by such
statements. These factors include those discussed inaap
's public reports. Forward-looking statements therefore speak only as of the
date they are made.aap
does not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or

For inquiries please contact:aap
Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin,

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail:


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.